Get started
Work

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
DOI: 10.1182/blood-2022-159823
Authors: Reid W Merryman, Robert A. Redd, Arnold S. Freedman, Inhye E. Ahn, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Eric D Jacobsen, Austin I. Kim, Ann S. LaCasce, Samuel Ng, Oreofe O. Odejide, Erin Michelle Parry, Iris Isufi, Justin Kline, Jonathon B. Cohen, Neha Mehta-Shah, Nancy L. Bartlett, Matthew Mei, Philippe Armand, Caron A. Jacobson
Institutions: Dana-Farber Cancer Institute, Yale University, University of Chicago, Emory University, Winship Cancer Institute, Washington University in St. Louis, City Of Hope National Medical Center, City of Hope
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W4310103263
FWCI: 0.141
Cites:
Cited by: 1
Related to: 10